The treatment of retinopathy of prematurity with Avastin

The Prevention of Blindness in Retinopathy of Prematurity by Intravitreal Injection of Bevacizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014101618966N2

Enrollment

Registered

2014-10-23

Start date

2012-01-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

A dose of bevacizumab of 0.625 mg in 0.025 ml was injected in each eye from the study sample, according to the following protocol: The pupils were dilated with a mixture of tropicamide 0.5% and phenyl

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

20 Days to 3 Months

Inclusion criteria

Inclusion criteria: Inclusion criteria: all the premature new borns that received intravitreal bevacizumab injections for retinopathy of prematurity

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Regression of retinopathy of prematurity. Timepoint: one week after the intravitreal injection of bevacizumab. Method of measurement: indirect ophthalmoscopy.	—

Secondary

Measure	Time frame
Condition of the retina. Timepoint: 52 weeks after the intravitreal injection of bevacizumab weeks. Method of measurement: indirect ophthalmocsopy.	—

Countries

Romania

Contacts

Public ContactNicoara Simona Delia

"Iuliu Hatieganu" University of Medicine and Pharmacy

simonanicoara1@gmail.com0040264597256

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026